United States: The researchers at Stanford Medicine discovered a natural compound that displays properties identical to the active element of diabetes medicine, which also leads to weight reduction.
More about the news
Research published in Nature proves that BRINP2-related peptide or BRP functions as a natural regulator of hunger and weight loss in both mice and pigs without the typical gastrointestinal side effects.
The research discovery provides hope to patients taking Wegovy or Ozempic by eliminating the significant side effects of pancreatic damage and vision issues while reducing thyroid cancer danger.
What more are the experts stating?
According to assistant professor of pathology Katrin Svensson, “The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues,” the Hill reported.
Furthermore, “That’s why Ozempic has widespread effects, including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism,” Svensson noted.
Sales of Ozempic and Wegovy have increased greatly during recent years, yet many patients struggle to obtain these drugs because of shortages and insurance limitations.
The Centers for Disease Control and Prevention reports that 100 million US adults qualify as obese based on a BMI of 30, and more than 22 million adults fit the classification of severe obesity at a BMI of 40 and higher, the Hill reported.